Edwards Lifesciences Corp (EW)

109.30
NYSE : Health Care
Prev Close 109.30
Day Low/High 0.00 / 0.00
52 Wk Low/High 81.12 / 121.75
Avg Volume 2.25M
Exchange NYSE
Shares Outstanding 211.19M
Market Cap 20.89B
EPS 2.70
P/E Ratio 37.90
Div & Yield N.A. (N.A)

Latest News

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

These stocks are indicating a change in direction.

Analysts' Actions -- CVS, Edwards Lifesciences, Qorvo, Tesoro and More

Analysts' Actions -- CVS, Edwards Lifesciences, Qorvo, Tesoro and More

Here are Thursday's top research calls, including downgrades for CVS, Edwards Lifesciences and Qorvo, and an upgrade for Tesoro.

Edwards Lifesciences Is Recovering From a Bearish Gap

Edwards Lifesciences Is Recovering From a Bearish Gap

However, more consolidation may be needed before the uptrend resumes.

Boost in Small-Business Confidence Is a Big Deal: Cramer's 'Mad Money' Recap

Boost in Small-Business Confidence Is a Big Deal: Cramer's 'Mad Money' Recap

The small business survey signals more building, more hiring, and more buying, Jim Cramer says.

Edwards Lifesciences Shows Signs of Life

Edwards Lifesciences Shows Signs of Life

Still, volume and positive money flow will need to improve to sustain a breakout move in the name.

These 5 Health Care Stocks Are Breaking Out This Christmas

These 5 Health Care Stocks Are Breaking Out This Christmas

The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.

Edwards' Life Goes On Without Big M&A

Edwards' Life Goes On Without Big M&A

As the dominant player in the transcatheter aortic valve replacement market, Edwards doesn't 'need' large deals.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

'Mad Money Lightning Round: Go Long on Pandora

'Mad Money Lightning Round: Go Long on Pandora

Cramer says he likes Twilio for the long term and is taking Nvidia over Himax.

Jim Cramer's 'Mad Money' Recap: Growth and Donald Trump Have Changed Everything

Jim Cramer's 'Mad Money' Recap: Growth and Donald Trump Have Changed Everything

When it comes to growth, what's good for the American people may also now be good for stocks, Cramer says.

Edwards Enters Into Agreement To Acquire Valtech Cardio

Edwards Enters Into Agreement To Acquire Valtech Cardio

Additionally, Edwards Board Approves New $1 Billion Share Repurchase Program

5 Health Care Stocks Set to Bounce

5 Health Care Stocks Set to Bounce

These stocks are down some 20% over the last 30 months and look ripe for a rise.

'Mad Money' Lightning Round: Brighter View for Some Insurers

'Mad Money' Lightning Round: Brighter View for Some Insurers

Jim Cramer says UVE is not bad, and he likes AIG and ALL as well.

Jim Cramer's 'Mad Money' Recap: Credibility Is the Most Valuable Currency for Investors

Jim Cramer's 'Mad Money' Recap: Credibility Is the Most Valuable Currency for Investors

Jim Cramer names companies with credibility, like NXPI and AAPL, and those that don't have it, including FIT.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Here's a window into what institutional investors may be doing and how to profit from that.

NXPI, AAPL, C: Jim Cramer's Views

NXPI, AAPL, C: Jim Cramer's Views

Cramer shares his views on takeover talks. NXP Semiconductor, Apple and Citigroup are among the stocks discussed.

Jim Cramer's 'Mad Money' Recap: Demand and Takeover Talk Lift Stocks

Jim Cramer's 'Mad Money' Recap: Demand and Takeover Talk Lift Stocks

Strong demand drives results and gains for Boeing, Akamai and others.

Cramer: Demand Lifts Defense, Aerospace, Cyber-Security, Regional Bank Stocks

Cramer: Demand Lifts Defense, Aerospace, Cyber-Security, Regional Bank Stocks

But several airline and retail stocks are proving highly volatile.

Edwards Lifesciences (EW) Stock Tumbles on Q3 Revenue Miss

Edwards Lifesciences (EW) Stock Tumbles on Q3 Revenue Miss

Edwards Lifesciences' (EW) 2016 third quarter revenue fell short of analysts' estimates.